AstraZeneca's Two Biggest Cancer Bets Just Hit the Same Wall
AstraZeneca faces an FDA advisory committee today with two precision oncology drugs that posted solid trial numbers. The problem: FDA reviewers think neither drug has clearly answered the questions that matter most.
The FDA Is Skeptical. AstraZeneca Has to Convince Them Anyway.
Imagine you're a student who designed your own exam, got a great score, and then the professor says: "Cool, but I'm not sure you actually answered the question."
That's roughly what's happening to AstraZeneca today. The FDA's Oncologic Drugs Advisory Committee (ODAC) is reviewing two of the company's precision oncology drugs in a single marathon session. Both face serious skepticism from FDA reviewers. Both could reshape how doctors treat specific cancer subtypes. And both might walk away empty-handed.
The morning session covers camizestrant, a next-generation pill for breast cancer patients whose tumors develop a specific escape mutation. The afternoon belongs to Truqap (capivasertib), which targets a genetic deficiency in prostate cancer. Together, these drugs represent a potential $5 billion-plus revenue opportunity for AstraZeneca.
The problem? The FDA thinks neither drug has proven its case clearly enough.
A Breast Cancer Drug That Catches Tumors Mid-Escape
To understand camizestrant, you need to understand ESR1 mutations. When breast cancer patients take aromatase inhibitors (drugs that starve tumors of estrogen), some tumors fight back. They develop ESR1 mutations that let the estrogen receptor activate on its own, like a car engine that keeps running after you remove the key.
This happens in up to 40% of advanced cases. Current practice: wait until scans show the cancer is growing again, then switch treatments. AstraZeneca's pitch is different. Why wait for the fire to spread when you can detect the smoke?
Camizestrant is an oral SERD (selective estrogen receptor degrader), a drug that physically destroys the estrogen receptor rather than just blocking it. In the SERENA-6 trial, patients whose blood tests detected ESR1 mutations were switched to camizestrant plus their existing CDK4/6 inhibitor before scans showed progression.
The results looked impressive. Median progression-free survival hit with camizestrant versus for patients who stayed on their original therapy. That's a 56% reduction in the risk of disease progression or death.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
16.0 months
9.2 months
Why the FDA Isn't Buying It (Yet)
So what's the catch? The trial compared switching early (at blood-test detection) to not switching at all. Patients in the control group stayed on their failing therapy even after scans confirmed progression. They weren't offered an oral SERD at that point.
The FDA's concern boils down to one uncomfortable question: did these patients benefit from camizestrant specifically, or would any oral SERD given at the right time have done the same job? There was no crossover built into the trial.
AstraZeneca argues that the FDA blessed this trial design back in 2021. They also point out that competing oral SERDs like Orserdu (elacestrant) deliver median PFS of only 3.8 months in later settings, making camizestrant's 16-month number look like a different league entirely.
But overall survival data won't be mature until approximately 2028. And the FDA briefing documents suggest the agency isn't convinced that progression-free survival alone tells the whole story here.
Truqap's Prostate Problem: The Effect Size Question
The afternoon session tackles Truqap's bid to expand into prostate cancer, specifically tumors that have lost a gene called PTEN.
PTEN normally acts as a brake on a growth-promoting pathway called PI3K/AKT. When PTEN is gone (which happens in 15-20% of early prostate cancers and 40-50% of metastatic cases), that brake disappears. The cancer accelerates. Patients progress faster to aggressive, treatment-resistant disease.
Truqap blocks AKT directly, restoring some of what PTEN loss takes away. Think of it as installing an aftermarket brake when the factory one fails.
In the CAPItello-281 trial, adding Truqap to abiraterone (a standard hormonal therapy) improved radiographic progression-free survival from 25.7 months to 33.2 months in PTEN-deficient patients with hormone-sensitive metastatic prostate cancer. That's a 7.5-month improvement and a 19% risk reduction.
A Statistically Significant Result the FDA Finds Clinically Underwhelming
Nineteen percent doesn't sound bad until you compare it to what the FDA has approved before in this space. Previous drugs for metastatic hormone-sensitive prostate cancer delivered much larger effect sizes on their way to approval.
The FDA also flags a tolerance issue. Most patients in this trial had minimal symptoms; fewer than 10% had meaningful pain progression. When patients feel relatively well, the bar for acceptable side effects drops considerably. Truqap's side effect profile includes diarrhea (52%), elevated blood sugar (38%), and rash (35%). Those numbers matter more when patients aren't suffering to begin with.
Overall survival data? Immature, with a hazard ratio of 0.90 that didn't reach statistical significance.
One interesting wrinkle: when researchers used stricter definitions of PTEN loss (requiring 95-100% of tumor cells to show the deficiency rather than 90%), the benefit grew stronger, with hazard ratios dropping to 0.75 and 0.68. This suggests the right patients might benefit meaningfully, but the current patient selection may be too broad.
What's at Stake Beyond AstraZeneca
This ODAC meeting isn't just about two drugs. It's a test case for biomarker-driven approvals in precision oncology. Both applications depend on companion diagnostics (blood tests for ESR1, tissue tests for PTEN) to identify the right patients. The FDA is essentially asking: how much benefit do biomarker-selected patients need to show before we call it clinically meaningful?
For breast cancer, camizestrant faces a crowded field. Elacestrant (Orserdu) won approval in 2023. Imlunestrant, vepdegestrant, and giredestrant are all advancing through late-stage trials. If camizestrant stumbles here, AstraZeneca won't have the market to itself for long.
For prostate cancer, the stakes are different. There's currently no approved therapy specifically targeting PTEN-deficient tumors. An approval would validate a new biomarker-driven approach in a space dominated by one-size-fits-all treatments.
The Bottom Line
Both drugs produced statistically significant results in well-run Phase 3 trials. Both target real biological vulnerabilities in specific cancer subtypes. And yet both face an FDA that wants more: clearer evidence that the benefit is clinically meaningful, not just statistically detectable.
The ODAC panel's votes today won't be binding, but they'll signal whether AstraZeneca's precision oncology strategy is ready for prime time or needs more time in the oven. The final PDUFA decisions will follow in the coming months.
Sometimes in drug development, having the right answer isn't enough. You also have to convince the professor you answered the right question.
4 min read
GSK Bet $700M on a Brain Theory. It Just Lost Twice.
GSK and Alector just killed their second Alzheimer's trial in six months, effectively torching a $700 million partnership. The failure raises uncomfortable questions about whether targeting the brain's immune system can actually slow neurodegeneration.
